News for hackers. Stuff that matters.
Re:Balaji Srinivasan, who may run the FDA for Trump, hates t... by anigbrowl on Tuesday January 17, 2017 @10:07PM (#13423655)
Then I'd say the primary problem is to reduce the cost of an access to clinical trials or improved flexibility in the trial requirements proportional to the size and plight of the patient population. The 'similar incentives' you mention are wanting to avoid public-health crises of the sort we have experienced many times in the past.

The trouble is that one does not see what was prevented from existing.

Opportunity cost is a basic fact of economics. It seems to me that people put a higher premium on reliability than novelty in this sphere; that is to say, the cost to society of people dying from terminal disease is less than that of people dying unexpectedly after treatment for less deadly conditions. Also, your statement assumes those cures will never be discoverable.

There are no comments on this comment yet.